All Articles
Later cancer treatment initiation and fewer treatment options once treatment starts are just some of the impacts of longer driving distances to treatment, according to researchers reporting in a study presented at the 66th Annual Meeting & Exposition held in San Diego, CA. Read More ›
US-Based Clinical Trials Actively Recruiting in Cancers of the Blood
Clinical trial recruitment and retention remain challenges in the quest to bring innovative therapies to all patients in need. In oncology, therapies continue to evolve, yet researchers are frequently faced with low trial participation,
particularly among minority groups. Read More ›
Fam-trastuzumab deruxtecan-nxki (Enhertu; Daiichi Sankyo) has been approved by FDA officials for use in patients with unresectable or metastatic hormone receptor (HR)-positive, HER2-low (IHC 1+ or IHC 2+/ISH-) or HER2-ultralow (IHC 0 with membrane staining) breast cancer, who have progressed on one or more endocrine therapies in the metastatic setting. Read More ›
On January 17, 2025, the FDA approved datopotamab deruxtecan-dlnk (Datroway; Daiichi Sankyo) for adult patients with unresectable or metastatic hormone receptor (HR)-positive, HER2-negative (IHC 0, IHC 1+ or IHC 2+/ISH-) breast cancer. Read More ›
The FDA has approved sotorasib (Lumakras; Amgen) with panitumumab (Vectibix; Amgen) for adult patients with KRAS G12C–mutated metastatic colorectal cancer (CRC), as determined by an FDA-approved test, who have received prior fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy. Read More ›
Acalabrutinib (Calquence; AstraZeneca) with bendamustine and rituximab has been greenlit for adults with previously untreated mantle cell lymphoma who are ineligible for autologous hematopoietic stem-cell transplantation. Read More ›
In the healthcare industry, financial collections are an unavoidable aspect of maintaining a sustainable practice. However, the sensitive nature of medical services requires a delicate balance between pursuing payments and preserving the patients’ trust and satisfaction. Successfully navigating this balance is crucial for the practice’s long-term success.
Read More ›
We are pleased to announce the release of our next issue of Clinical Trials to Clinical Practice. This article provides expert commentary from Joyce A. O’Shaughnessy, MD, on the use of endocrine therapy with or without adjuvant abemaciclib for patients with high-risk, hormone receptor (HR)-positive, HER2-negative early breast cancer. Read More ›
The common issue addressed by lawsuits is the removal of human beings to review and make determinations regarding the appropriateness of care. While mainly focused now on algorithms, these factors seem to be an indicator of future health plan litigation involving artificial intelligence. Read More ›
A lab created a drug-matching platform that uses artificial intelligence (AI) to help researchers, clinicians and, most importantly, patients find additional uses for drugs that have already gone through clinical trials and received approval from the FDA. Read More ›